Top in ID: CDC mask guidance, mRNA-based RSV vaccine

The CDC recently revised its guidance on the use of face masks. Based on the agency’s new COVID-19 metrics, which rely on local measures of hospital capacity, around 70% of people live in areas where they can go without a mask.

A review of the guidance was the top story in infectious disease last week.

Another top story was about the launch of Moderna’s phase 3 study for its investigational messenger RNA-based RSV vaccine. The company is also testing an mRNA vaccine for influenza and has said that its goal is to create combination vaccines for several respiratory viruses, including influenza, SARS-CoV-2 and RSV.

Read these and more top stories in infectious disease below:

CDC’s new COVID-19 metrics indicate most Americans can go maskless

New COVID-19 guidance released by the CDC indicates that most Americans now live in areas where they can go maskless. Read more.

Moderna starts phase 3 study of messenger RNA-based RSV vaccine

Moderna announced that it has initiated a phase 3 study of its investigational mRNA-based vaccine for RSV. Read more.

Interval between COVID-19 vaccine doses can be 8 weeks for some people, CDC says

The interval between the first and second doses of the Pfizer-BioNTech and Moderna COVID-19 vaccines can be 8 weeks for certain people, the CDC said in updated interim guidance. Read more.

Sanofi, GSK will seek authorization for COVID-19 vaccine

Sanofi and GSK announced that they will submit data from booster and phase 3 efficacy trials to support authorization of their two-dose protein-based COVID-19 vaccine. Read more.

CDC recommends 4-month regimen for drug-susceptible TB

The CDC published a recommendation and interim guidance in MMWR for a 4-month regimen to treat patients aged 12 years or older with drug-susceptible pulmonary tuberculosis. Read more.